Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Netanyahu leads meeting on West Bank riots, Katz defends axing administrative detention for Jews - 2Court clears Beersheba assault suspect of link to Haymanut Kasau disappearance, extends detention
- 3Instructions to Pick the Best Album Rates for Your Investment funds
- 4Picking the Right Pot for Your Plants: An Aide for Plant Devotees
- 5See the first close-up photos of the moon from NASA's Artemis II mission
- Pick Your #1 Japanese Food
- Australian State Triggers Emergency Powers Amid Fuel Crisis
- 5 Morning Schedules That Stimulate Your Day
- How to get tickets for AC/DC's 2026 'Power Up' Tour
- The Fate of Mechanical technology: 5 Headways Forming Tomorrow
- Distributed storage Answers for Information Reinforcement
- RSF attack on Sudan’s South Kordofan kills at least 14, including children
- Vote In favor of Your Favored Kind Of Tea
- San Francisco sues 10 companies that make ultraprocessed food
